Medigus Ltd. American Depositary Share Stock Price, News & Analysis

Medigus Ltd. (Nasdaq: MDGS) announced its 47.69% owned subsidiary, Eventer Technologies Ltd., signed contracts with Israel Gymnastics Federation and Table Tennis Association. Eventer is focused on expanding its services beyond entertainment into sports by providing a platform for virtual events and smart ticketing solutions. The collaboration aims to enhance global ticket sales and event promotion. Eventer will also supply video production and marketing services for broadcasts of the events.

Medigus (Nasdaq: MDGS) announced a partnership between its subsidiary Charging Robotics and BGN Technologies to develop a next-generation wireless charging system for electric vehicles (EVs). This innovative technology aims to address the growing need for convenient and cost-effective charging solutions, particularly as EV sales surge. The system, to be installed in public lots, will use a dedicated robot to automatically recharge EVs, operating at 12kW, which aligns with standard residential chargers. The collaboration with Ben-Gurion University will leverage advanced energy transmission research.

Medigus Ltd. (Nasdaq: MDGS) announced that ParaZero Ltd., in which it holds a 40% stake, has received Brazil's first authorization for commercial drone deliveries from ANAC. This authorization allows the DLV-1 NEO drone to operate beyond visual line of sight, carrying loads up to 2.5 kg within a 3 km radius. ParaZero's patented SafeAir system enhances drone safety with a real-time monitoring smart parachute. The commercial drone market is anticipated to reach $85 billion by 2025, emphasizing the significance of this development in opening new business opportunities for commercial operators.

Medigus Ltd. (MDGS) has announced a strategic investment in Clearmind Medicine Inc., committing US $1.25 million to acquire approximately 2 million units (5.02% equity). This investment aims to expand Medigus' healthcare involvement, particularly in developing psychedelic-derived therapeutics. The joint venture will focus on food supplements based on Clearmind's intellectual property, alongside the goal of regulatory approvals for product distribution. The psychedelic market is projected to grow to USD $10.75 billion by 2027.

Medigus Ltd. (Nasdaq: MDGS) has acquired approximately 40% of an Israeli drone technology company known for its patented safety system designed to prevent drone crashes. This innovative system features a smart parachute that autonomously deploys during emergencies, addressing safety concerns for commercial drones operating near people and structures. With over 870,000 registered drones in the U.S., this investment taps into a multi-billion-dollar market. The technology complies with FAA regulations and is currently being commercialized globally.

Medigus Ltd. (Nasdaq: MDGS) announced an upcoming interview featuring Chairman Eli Yoresh and VP of Strategy Yaki Baranes on The RedChip Money Report® airing on Bloomberg TV on January 29 at 7 p.m. ET. This program, known for insights into small-cap investing, reaches approximately 73 million homes in the U.S. Medigus is involved in advanced medical solutions, electric vehicles, and digital commerce, with various affiliations in these sectors. For viewing details, visit this link.

Medigus Ltd. (Nasdaq: MDGS) announced that its 47.69% owned subsidiary, Eventer Technologies Ltd., submitted a draft registration statement on Form F-1 to the SEC for a potential IPO of its shares in the U.S. Eventer specializes in cloud-based ticketing solutions for various events, including in-person, virtual, and hybrid formats. The specific timing, number of shares, and pricing for the offering remain undetermined. This initiative aims to leverage Eventer's innovative technology platform to enhance shareholder value.

Medigus Ltd. (Nasdaq: MDGS) announced promising results from pre-clinical studies conducted by its affiliate, Polyrizon Ltd. Recent findings indicate that Polyrizon's products may prevent interactions between human coronavirus 229E, Influenza Virus H1N1, and epithelial host cells, thereby inhibiting cell death. The company plans to evaluate the efficacy of its innovative product candidate against the Omicron variant (B.1.1.529) in Q1 2022 in collaboration with a professor from Parma University. This highlights the ongoing need for preventive solutions against highly transmissible COVID-19 variants.

Medigus Ltd. (Nasdaq: MDGS) has filed a motion for court approval to increase its buyback program from $2 million to $3 million. This buyback initiative aims to enhance shareholder value and is expected to begin in Q1 2022, contingent upon court approval. The company is involved in advanced medical solutions and innovative technologies, with affiliations in digital commerce and electric vehicle sectors. The successful implementation of the buyback could positively impact stock performance by reducing available shares.